nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftriaxone—SLC22A11—Methotrexate—urinary bladder cancer	0.154	0.338	CbGbCtD
Ceftriaxone—ALB—Fluorouracil—urinary bladder cancer	0.0964	0.212	CbGbCtD
Ceftriaxone—SLC22A8—Methotrexate—urinary bladder cancer	0.0896	0.197	CbGbCtD
Ceftriaxone—SLC22A6—Methotrexate—urinary bladder cancer	0.0624	0.137	CbGbCtD
Ceftriaxone—ALB—Methotrexate—urinary bladder cancer	0.0532	0.117	CbGbCtD
Ceftriaxone—SLC22A8—urine—urinary bladder cancer	0.0146	0.125	CbGeAlD
Ceftriaxone—GLUL—prostate gland—urinary bladder cancer	0.00884	0.0756	CbGeAlD
Ceftriaxone—GLUL—epithelium—urinary bladder cancer	0.0065	0.0555	CbGeAlD
Ceftriaxone—SLC22A11—renal system—urinary bladder cancer	0.00635	0.0543	CbGeAlD
Ceftriaxone—GLUL—smooth muscle tissue—urinary bladder cancer	0.00626	0.0535	CbGeAlD
Ceftriaxone—GLUL—renal system—urinary bladder cancer	0.00603	0.0515	CbGeAlD
Ceftriaxone—GLUL—urethra—urinary bladder cancer	0.00592	0.0506	CbGeAlD
Ceftriaxone—SLC15A1—epithelium—urinary bladder cancer	0.00537	0.0459	CbGeAlD
Ceftriaxone—SLC22A8—prostate gland—urinary bladder cancer	0.00526	0.0449	CbGeAlD
Ceftriaxone—SLC22A11—female reproductive system—urinary bladder cancer	0.00509	0.0435	CbGeAlD
Ceftriaxone—SLC15A1—renal system—urinary bladder cancer	0.00498	0.0426	CbGeAlD
Ceftriaxone—GLUL—female reproductive system—urinary bladder cancer	0.00483	0.0412	CbGeAlD
Ceftriaxone—SLC15A2—prostate gland—urinary bladder cancer	0.00457	0.039	CbGeAlD
Ceftriaxone—GLUL—vagina—urinary bladder cancer	0.00436	0.0373	CbGeAlD
Ceftriaxone—SLC15A2—seminal vesicle—urinary bladder cancer	0.00386	0.033	CbGeAlD
Ceftriaxone—SLC15A1—vagina—urinary bladder cancer	0.00361	0.0308	CbGeAlD
Ceftriaxone—SLC22A8—renal system—urinary bladder cancer	0.00358	0.0306	CbGeAlD
Ceftriaxone—SLC15A2—renal system—urinary bladder cancer	0.00311	0.0266	CbGeAlD
Ceftriaxone—SLC15A2—urethra—urinary bladder cancer	0.00306	0.0261	CbGeAlD
Ceftriaxone—GLUL—lymph node—urinary bladder cancer	0.00282	0.0241	CbGeAlD
Ceftriaxone—SLC15A2—female reproductive system—urinary bladder cancer	0.00249	0.0213	CbGeAlD
Ceftriaxone—SLC15A2—vagina—urinary bladder cancer	0.00226	0.0193	CbGeAlD
Ceftriaxone—ALB—lymph node—urinary bladder cancer	0.00175	0.0149	CbGeAlD
Ceftriaxone—SLC15A2—lymph node—urinary bladder cancer	0.00146	0.0125	CbGeAlD
Ceftriaxone—Discomfort—Gemcitabine—urinary bladder cancer	0.000692	0.00162	CcSEcCtD
Ceftriaxone—Malaise—Cisplatin—urinary bladder cancer	0.000691	0.00162	CcSEcCtD
Ceftriaxone—Dysgeusia—Etoposide—urinary bladder cancer	0.000688	0.00161	CcSEcCtD
Ceftriaxone—Renal impairment—Epirubicin—urinary bladder cancer	0.000687	0.00161	CcSEcCtD
Ceftriaxone—Leukopenia—Cisplatin—urinary bladder cancer	0.000686	0.00161	CcSEcCtD
Ceftriaxone—Pain—Thiotepa—urinary bladder cancer	0.000682	0.0016	CcSEcCtD
Ceftriaxone—Discomfort—Fluorouracil—urinary bladder cancer	0.00068	0.00159	CcSEcCtD
Ceftriaxone—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.000675	0.00158	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000671	0.00157	CcSEcCtD
Ceftriaxone—Oedema—Gemcitabine—urinary bladder cancer	0.000671	0.00157	CcSEcCtD
Ceftriaxone—Infection—Gemcitabine—urinary bladder cancer	0.000667	0.00156	CcSEcCtD
Ceftriaxone—Convulsion—Cisplatin—urinary bladder cancer	0.000664	0.00155	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00066	0.00154	CcSEcCtD
Ceftriaxone—Oedema—Fluorouracil—urinary bladder cancer	0.00066	0.00154	CcSEcCtD
Ceftriaxone—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000658	0.00154	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000657	0.00154	CcSEcCtD
Ceftriaxone—Ataxia—Methotrexate—urinary bladder cancer	0.000657	0.00154	CcSEcCtD
Ceftriaxone—Infection—Fluorouracil—urinary bladder cancer	0.000656	0.00153	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000653	0.00153	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Etoposide—urinary bladder cancer	0.000652	0.00153	CcSEcCtD
Ceftriaxone—Anaemia—Etoposide—urinary bladder cancer	0.000649	0.00152	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000649	0.00152	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000646	0.00151	CcSEcCtD
Ceftriaxone—Discomfort—Cisplatin—urinary bladder cancer	0.000645	0.00151	CcSEcCtD
Ceftriaxone—Dermatitis exfoliative—Doxorubicin—urinary bladder cancer	0.000641	0.0015	CcSEcCtD
Ceftriaxone—Renal impairment—Doxorubicin—urinary bladder cancer	0.000636	0.00149	CcSEcCtD
Ceftriaxone—Urticaria—Thiotepa—urinary bladder cancer	0.000634	0.00148	CcSEcCtD
Ceftriaxone—Malaise—Etoposide—urinary bladder cancer	0.000633	0.00148	CcSEcCtD
Ceftriaxone—Body temperature increased—Thiotepa—urinary bladder cancer	0.000631	0.00148	CcSEcCtD
Ceftriaxone—Abdominal pain—Thiotepa—urinary bladder cancer	0.000631	0.00148	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.000629	0.00147	CcSEcCtD
Ceftriaxone—Leukopenia—Etoposide—urinary bladder cancer	0.000629	0.00147	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000626	0.00146	CcSEcCtD
Ceftriaxone—Oedema—Cisplatin—urinary bladder cancer	0.000626	0.00146	CcSEcCtD
Ceftriaxone—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.000625	0.00146	CcSEcCtD
Ceftriaxone—Infection—Cisplatin—urinary bladder cancer	0.000622	0.00145	CcSEcCtD
Ceftriaxone—Ataxia—Epirubicin—urinary bladder cancer	0.000615	0.00144	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000613	0.00143	CcSEcCtD
Ceftriaxone—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000612	0.00143	CcSEcCtD
Ceftriaxone—Convulsion—Etoposide—urinary bladder cancer	0.000609	0.00142	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000605	0.00142	CcSEcCtD
Ceftriaxone—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000603	0.00141	CcSEcCtD
Ceftriaxone—Eosinophilia—Methotrexate—urinary bladder cancer	0.000598	0.0014	CcSEcCtD
Ceftriaxone—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000597	0.0014	CcSEcCtD
Ceftriaxone—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000593	0.00139	CcSEcCtD
Ceftriaxone—Pancreatitis—Methotrexate—urinary bladder cancer	0.000592	0.00139	CcSEcCtD
Ceftriaxone—Discomfort—Etoposide—urinary bladder cancer	0.000591	0.00138	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000589	0.00138	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000589	0.00138	CcSEcCtD
Ceftriaxone—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000588	0.00138	CcSEcCtD
Ceftriaxone—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000581	0.00136	CcSEcCtD
Ceftriaxone—Pain—Gemcitabine—urinary bladder cancer	0.000574	0.00134	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000573	0.00134	CcSEcCtD
Ceftriaxone—Infection—Etoposide—urinary bladder cancer	0.000569	0.00133	CcSEcCtD
Ceftriaxone—Ataxia—Doxorubicin—urinary bladder cancer	0.000569	0.00133	CcSEcCtD
Ceftriaxone—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000567	0.00133	CcSEcCtD
Ceftriaxone—Neutropenia—Methotrexate—urinary bladder cancer	0.000565	0.00132	CcSEcCtD
Ceftriaxone—Pruritus—Thiotepa—urinary bladder cancer	0.000565	0.00132	CcSEcCtD
Ceftriaxone—Pain—Fluorouracil—urinary bladder cancer	0.000564	0.00132	CcSEcCtD
Ceftriaxone—Paraesthesia—Cisplatin—urinary bladder cancer	0.000562	0.00131	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000561	0.00131	CcSEcCtD
Ceftriaxone—Eosinophilia—Epirubicin—urinary bladder cancer	0.000559	0.00131	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000554	0.0013	CcSEcCtD
Ceftriaxone—Pancreatitis—Epirubicin—urinary bladder cancer	0.000554	0.0013	CcSEcCtD
Ceftriaxone—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000553	0.00129	CcSEcCtD
Ceftriaxone—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000552	0.00129	CcSEcCtD
Ceftriaxone—Diarrhoea—Thiotepa—urinary bladder cancer	0.000546	0.00128	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000545	0.00127	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000545	0.00127	CcSEcCtD
Ceftriaxone—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000544	0.00127	CcSEcCtD
Ceftriaxone—Pain—Cisplatin—urinary bladder cancer	0.000535	0.00125	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000534	0.00125	CcSEcCtD
Ceftriaxone—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000531	0.00124	CcSEcCtD
Ceftriaxone—Renal failure—Methotrexate—urinary bladder cancer	0.000529	0.00124	CcSEcCtD
Ceftriaxone—Neutropenia—Epirubicin—urinary bladder cancer	0.000528	0.00124	CcSEcCtD
Ceftriaxone—Dizziness—Thiotepa—urinary bladder cancer	0.000528	0.00123	CcSEcCtD
Ceftriaxone—Stomatitis—Methotrexate—urinary bladder cancer	0.000525	0.00123	CcSEcCtD
Ceftriaxone—Urticaria—Fluorouracil—urinary bladder cancer	0.000524	0.00123	CcSEcCtD
Ceftriaxone—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000522	0.00122	CcSEcCtD
Ceftriaxone—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000518	0.00121	CcSEcCtD
Ceftriaxone—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000516	0.00121	CcSEcCtD
Ceftriaxone—Paraesthesia—Etoposide—urinary bladder cancer	0.000515	0.0012	CcSEcCtD
Ceftriaxone—Haematuria—Methotrexate—urinary bladder cancer	0.000513	0.0012	CcSEcCtD
Ceftriaxone—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000513	0.0012	CcSEcCtD
Ceftriaxone—Epistaxis—Methotrexate—urinary bladder cancer	0.000508	0.00119	CcSEcCtD
Ceftriaxone—Vomiting—Thiotepa—urinary bladder cancer	0.000507	0.00119	CcSEcCtD
Ceftriaxone—Rash—Thiotepa—urinary bladder cancer	0.000503	0.00118	CcSEcCtD
Ceftriaxone—Dermatitis—Thiotepa—urinary bladder cancer	0.000503	0.00118	CcSEcCtD
Ceftriaxone—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000502	0.00118	CcSEcCtD
Ceftriaxone—Headache—Thiotepa—urinary bladder cancer	0.0005	0.00117	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000499	0.00117	CcSEcCtD
Ceftriaxone—Renal failure—Epirubicin—urinary bladder cancer	0.000495	0.00116	CcSEcCtD
Ceftriaxone—Body temperature increased—Cisplatin—urinary bladder cancer	0.000495	0.00116	CcSEcCtD
Ceftriaxone—Jaundice—Epirubicin—urinary bladder cancer	0.000491	0.00115	CcSEcCtD
Ceftriaxone—Stomatitis—Epirubicin—urinary bladder cancer	0.000491	0.00115	CcSEcCtD
Ceftriaxone—Pain—Etoposide—urinary bladder cancer	0.00049	0.00115	CcSEcCtD
Ceftriaxone—Neutropenia—Doxorubicin—urinary bladder cancer	0.000489	0.00114	CcSEcCtD
Ceftriaxone—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000486	0.00114	CcSEcCtD
Ceftriaxone—Haemoglobin—Methotrexate—urinary bladder cancer	0.000486	0.00114	CcSEcCtD
Ceftriaxone—Haemorrhage—Methotrexate—urinary bladder cancer	0.000483	0.00113	CcSEcCtD
Ceftriaxone—Haematuria—Epirubicin—urinary bladder cancer	0.00048	0.00112	CcSEcCtD
Ceftriaxone—Epistaxis—Epirubicin—urinary bladder cancer	0.000475	0.00111	CcSEcCtD
Ceftriaxone—Pruritus—Gemcitabine—urinary bladder cancer	0.000475	0.00111	CcSEcCtD
Ceftriaxone—Nausea—Thiotepa—urinary bladder cancer	0.000474	0.00111	CcSEcCtD
Ceftriaxone—Feeling abnormal—Etoposide—urinary bladder cancer	0.000472	0.00111	CcSEcCtD
Ceftriaxone—Agranulocytosis—Epirubicin—urinary bladder cancer	0.00047	0.0011	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000469	0.0011	CcSEcCtD
Ceftriaxone—Pruritus—Fluorouracil—urinary bladder cancer	0.000467	0.00109	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000462	0.00108	CcSEcCtD
Ceftriaxone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000461	0.00108	CcSEcCtD
Ceftriaxone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000459	0.00107	CcSEcCtD
Ceftriaxone—Renal failure—Doxorubicin—urinary bladder cancer	0.000458	0.00107	CcSEcCtD
Ceftriaxone—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000457	0.00107	CcSEcCtD
Ceftriaxone—Urticaria—Etoposide—urinary bladder cancer	0.000455	0.00107	CcSEcCtD
Ceftriaxone—Haemoglobin—Epirubicin—urinary bladder cancer	0.000455	0.00106	CcSEcCtD
Ceftriaxone—Stomatitis—Doxorubicin—urinary bladder cancer	0.000454	0.00106	CcSEcCtD
Ceftriaxone—Jaundice—Doxorubicin—urinary bladder cancer	0.000454	0.00106	CcSEcCtD
Ceftriaxone—Abdominal pain—Etoposide—urinary bladder cancer	0.000453	0.00106	CcSEcCtD
Ceftriaxone—Body temperature increased—Etoposide—urinary bladder cancer	0.000453	0.00106	CcSEcCtD
Ceftriaxone—Haemorrhage—Epirubicin—urinary bladder cancer	0.000452	0.00106	CcSEcCtD
Ceftriaxone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000452	0.00106	CcSEcCtD
Ceftriaxone—Haematuria—Doxorubicin—urinary bladder cancer	0.000444	0.00104	CcSEcCtD
Ceftriaxone—Epistaxis—Doxorubicin—urinary bladder cancer	0.00044	0.00103	CcSEcCtD
Ceftriaxone—Dizziness—Fluorouracil—urinary bladder cancer	0.000436	0.00102	CcSEcCtD
Ceftriaxone—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000435	0.00102	CcSEcCtD
Ceftriaxone—Chills—Methotrexate—urinary bladder cancer	0.000434	0.00101	CcSEcCtD
Ceftriaxone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000428	0.001	CcSEcCtD
Ceftriaxone—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000428	0.001	CcSEcCtD
Ceftriaxone—Vomiting—Gemcitabine—urinary bladder cancer	0.000427	0.000999	CcSEcCtD
Ceftriaxone—Rash—Gemcitabine—urinary bladder cancer	0.000423	0.000991	CcSEcCtD
Ceftriaxone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000423	0.00099	CcSEcCtD
Ceftriaxone—Hypersensitivity—Etoposide—urinary bladder cancer	0.000422	0.000988	CcSEcCtD
Ceftriaxone—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000421	0.000984	CcSEcCtD
Ceftriaxone—Headache—Gemcitabine—urinary bladder cancer	0.000421	0.000984	CcSEcCtD
Ceftriaxone—Flushing—Epirubicin—urinary bladder cancer	0.00042	0.000982	CcSEcCtD
Ceftriaxone—Vomiting—Fluorouracil—urinary bladder cancer	0.00042	0.000982	CcSEcCtD
Ceftriaxone—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000418	0.000979	CcSEcCtD
Ceftriaxone—Rash—Fluorouracil—urinary bladder cancer	0.000416	0.000974	CcSEcCtD
Ceftriaxone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000416	0.000973	CcSEcCtD
Ceftriaxone—Headache—Fluorouracil—urinary bladder cancer	0.000413	0.000968	CcSEcCtD
Ceftriaxone—Dysgeusia—Methotrexate—urinary bladder cancer	0.000412	0.000964	CcSEcCtD
Ceftriaxone—Chills—Epirubicin—urinary bladder cancer	0.000406	0.00095	CcSEcCtD
Ceftriaxone—Pruritus—Etoposide—urinary bladder cancer	0.000406	0.000949	CcSEcCtD
Ceftriaxone—Nausea—Gemcitabine—urinary bladder cancer	0.000399	0.000933	CcSEcCtD
Ceftriaxone—Vomiting—Cisplatin—urinary bladder cancer	0.000398	0.000931	CcSEcCtD
Ceftriaxone—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000396	0.000926	CcSEcCtD
Ceftriaxone—Rash—Cisplatin—urinary bladder cancer	0.000394	0.000923	CcSEcCtD
Ceftriaxone—Dermatitis—Cisplatin—urinary bladder cancer	0.000394	0.000922	CcSEcCtD
Ceftriaxone—Diarrhoea—Etoposide—urinary bladder cancer	0.000392	0.000918	CcSEcCtD
Ceftriaxone—Nausea—Fluorouracil—urinary bladder cancer	0.000392	0.000917	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00039	0.000914	CcSEcCtD
Ceftriaxone—Anaemia—Methotrexate—urinary bladder cancer	0.000389	0.00091	CcSEcCtD
Ceftriaxone—Flushing—Doxorubicin—urinary bladder cancer	0.000388	0.000909	CcSEcCtD
Ceftriaxone—Flatulence—Epirubicin—urinary bladder cancer	0.000388	0.000908	CcSEcCtD
Ceftriaxone—Dysgeusia—Epirubicin—urinary bladder cancer	0.000386	0.000902	CcSEcCtD
Ceftriaxone—Malaise—Methotrexate—urinary bladder cancer	0.000379	0.000888	CcSEcCtD
Ceftriaxone—Dizziness—Etoposide—urinary bladder cancer	0.000379	0.000887	CcSEcCtD
Ceftriaxone—Leukopenia—Methotrexate—urinary bladder cancer	0.000377	0.000881	CcSEcCtD
Ceftriaxone—Chills—Doxorubicin—urinary bladder cancer	0.000375	0.000879	CcSEcCtD
Ceftriaxone—Nausea—Cisplatin—urinary bladder cancer	0.000372	0.00087	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000365	0.000855	CcSEcCtD
Ceftriaxone—Convulsion—Methotrexate—urinary bladder cancer	0.000364	0.000853	CcSEcCtD
Ceftriaxone—Vomiting—Etoposide—urinary bladder cancer	0.000364	0.000853	CcSEcCtD
Ceftriaxone—Anaemia—Epirubicin—urinary bladder cancer	0.000364	0.000852	CcSEcCtD
Ceftriaxone—Agitation—Epirubicin—urinary bladder cancer	0.000362	0.000847	CcSEcCtD
Ceftriaxone—Rash—Etoposide—urinary bladder cancer	0.000361	0.000846	CcSEcCtD
Ceftriaxone—Dermatitis—Etoposide—urinary bladder cancer	0.000361	0.000845	CcSEcCtD
Ceftriaxone—Headache—Etoposide—urinary bladder cancer	0.000359	0.00084	CcSEcCtD
Ceftriaxone—Flatulence—Doxorubicin—urinary bladder cancer	0.000359	0.00084	CcSEcCtD
Ceftriaxone—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000357	0.000835	CcSEcCtD
Ceftriaxone—Malaise—Epirubicin—urinary bladder cancer	0.000355	0.000831	CcSEcCtD
Ceftriaxone—Discomfort—Methotrexate—urinary bladder cancer	0.000354	0.000828	CcSEcCtD
Ceftriaxone—Leukopenia—Epirubicin—urinary bladder cancer	0.000352	0.000825	CcSEcCtD
Ceftriaxone—Palpitations—Epirubicin—urinary bladder cancer	0.000348	0.000814	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000343	0.000804	CcSEcCtD
Ceftriaxone—Convulsion—Epirubicin—urinary bladder cancer	0.000341	0.000798	CcSEcCtD
Ceftriaxone—Infection—Methotrexate—urinary bladder cancer	0.000341	0.000798	CcSEcCtD
Ceftriaxone—Nausea—Etoposide—urinary bladder cancer	0.00034	0.000797	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000338	0.000791	CcSEcCtD
Ceftriaxone—Anaemia—Doxorubicin—urinary bladder cancer	0.000337	0.000788	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000336	0.000787	CcSEcCtD
Ceftriaxone—Agitation—Doxorubicin—urinary bladder cancer	0.000335	0.000783	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000332	0.000777	CcSEcCtD
Ceftriaxone—Discomfort—Epirubicin—urinary bladder cancer	0.000331	0.000775	CcSEcCtD
Ceftriaxone—Malaise—Doxorubicin—urinary bladder cancer	0.000328	0.000769	CcSEcCtD
Ceftriaxone—Leukopenia—Doxorubicin—urinary bladder cancer	0.000326	0.000763	CcSEcCtD
Ceftriaxone—Palpitations—Doxorubicin—urinary bladder cancer	0.000322	0.000753	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000321	0.000752	CcSEcCtD
Ceftriaxone—Oedema—Epirubicin—urinary bladder cancer	0.000321	0.000752	CcSEcCtD
Ceftriaxone—Infection—Epirubicin—urinary bladder cancer	0.000319	0.000747	CcSEcCtD
Ceftriaxone—Convulsion—Doxorubicin—urinary bladder cancer	0.000316	0.000739	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000315	0.000736	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000311	0.000727	CcSEcCtD
Ceftriaxone—Paraesthesia—Methotrexate—urinary bladder cancer	0.000308	0.000722	CcSEcCtD
Ceftriaxone—Discomfort—Doxorubicin—urinary bladder cancer	0.000306	0.000717	CcSEcCtD
Ceftriaxone—Dyspepsia—Methotrexate—urinary bladder cancer	0.000302	0.000707	CcSEcCtD
Ceftriaxone—Oedema—Doxorubicin—urinary bladder cancer	0.000297	0.000696	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000297	0.000696	CcSEcCtD
Ceftriaxone—Infection—Doxorubicin—urinary bladder cancer	0.000295	0.000691	CcSEcCtD
Ceftriaxone—Pain—Methotrexate—urinary bladder cancer	0.000294	0.000687	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000291	0.000681	CcSEcCtD
Ceftriaxone—Paraesthesia—Epirubicin—urinary bladder cancer	0.000289	0.000675	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000287	0.000673	CcSEcCtD
Ceftriaxone—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000283	0.000662	CcSEcCtD
Ceftriaxone—Dyspepsia—Epirubicin—urinary bladder cancer	0.000283	0.000662	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000281	0.000657	CcSEcCtD
Ceftriaxone—Pain—Epirubicin—urinary bladder cancer	0.000275	0.000643	CcSEcCtD
Ceftriaxone—Urticaria—Methotrexate—urinary bladder cancer	0.000273	0.000638	CcSEcCtD
Ceftriaxone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000271	0.000635	CcSEcCtD
Ceftriaxone—Body temperature increased—Methotrexate—urinary bladder cancer	0.000271	0.000635	CcSEcCtD
Ceftriaxone—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000267	0.000625	CcSEcCtD
Ceftriaxone—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000265	0.00062	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000263	0.000615	CcSEcCtD
Ceftriaxone—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000262	0.000612	CcSEcCtD
Ceftriaxone—Urticaria—Epirubicin—urinary bladder cancer	0.000255	0.000597	CcSEcCtD
Ceftriaxone—Pain—Doxorubicin—urinary bladder cancer	0.000254	0.000595	CcSEcCtD
Ceftriaxone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000254	0.000594	CcSEcCtD
Ceftriaxone—Body temperature increased—Epirubicin—urinary bladder cancer	0.000254	0.000594	CcSEcCtD
Ceftriaxone—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000253	0.000592	CcSEcCtD
Ceftriaxone—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000245	0.000573	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000243	0.000569	CcSEcCtD
Ceftriaxone—Pruritus—Methotrexate—urinary bladder cancer	0.000243	0.000568	CcSEcCtD
Ceftriaxone—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000237	0.000554	CcSEcCtD
Ceftriaxone—Urticaria—Doxorubicin—urinary bladder cancer	0.000236	0.000553	CcSEcCtD
Ceftriaxone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000235	0.00055	CcSEcCtD
Ceftriaxone—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000235	0.00055	CcSEcCtD
Ceftriaxone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000235	0.00055	CcSEcCtD
Ceftriaxone—Pruritus—Epirubicin—urinary bladder cancer	0.000227	0.000532	CcSEcCtD
Ceftriaxone—Dizziness—Methotrexate—urinary bladder cancer	0.000227	0.000531	CcSEcCtD
Ceftriaxone—Diarrhoea—Epirubicin—urinary bladder cancer	0.00022	0.000515	CcSEcCtD
Ceftriaxone—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000219	0.000513	CcSEcCtD
Ceftriaxone—Vomiting—Methotrexate—urinary bladder cancer	0.000218	0.000511	CcSEcCtD
Ceftriaxone—Rash—Methotrexate—urinary bladder cancer	0.000216	0.000507	CcSEcCtD
Ceftriaxone—Dermatitis—Methotrexate—urinary bladder cancer	0.000216	0.000506	CcSEcCtD
Ceftriaxone—Headache—Methotrexate—urinary bladder cancer	0.000215	0.000503	CcSEcCtD
Ceftriaxone—Dizziness—Epirubicin—urinary bladder cancer	0.000212	0.000497	CcSEcCtD
Ceftriaxone—Pruritus—Doxorubicin—urinary bladder cancer	0.00021	0.000492	CcSEcCtD
Ceftriaxone—Vomiting—Epirubicin—urinary bladder cancer	0.000204	0.000478	CcSEcCtD
Ceftriaxone—Nausea—Methotrexate—urinary bladder cancer	0.000204	0.000477	CcSEcCtD
Ceftriaxone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000203	0.000476	CcSEcCtD
Ceftriaxone—Rash—Epirubicin—urinary bladder cancer	0.000203	0.000474	CcSEcCtD
Ceftriaxone—Dermatitis—Epirubicin—urinary bladder cancer	0.000202	0.000474	CcSEcCtD
Ceftriaxone—Headache—Epirubicin—urinary bladder cancer	0.000201	0.000471	CcSEcCtD
Ceftriaxone—Dizziness—Doxorubicin—urinary bladder cancer	0.000197	0.00046	CcSEcCtD
Ceftriaxone—Nausea—Epirubicin—urinary bladder cancer	0.000191	0.000447	CcSEcCtD
Ceftriaxone—Vomiting—Doxorubicin—urinary bladder cancer	0.000189	0.000442	CcSEcCtD
Ceftriaxone—Rash—Doxorubicin—urinary bladder cancer	0.000187	0.000439	CcSEcCtD
Ceftriaxone—Dermatitis—Doxorubicin—urinary bladder cancer	0.000187	0.000438	CcSEcCtD
Ceftriaxone—Headache—Doxorubicin—urinary bladder cancer	0.000186	0.000436	CcSEcCtD
Ceftriaxone—Nausea—Doxorubicin—urinary bladder cancer	0.000177	0.000413	CcSEcCtD
